Literature DB >> 18419454

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation.

Michael Y Shapira1, Igor B Resnick, Sunwen Chou, Avidan U Neumann, Nell S Lurain, Thomas Stamminger, Orit Caplan, Niveen Saleh, Thomas Efferth, Manfred Marschall, Dana G Wolf.   

Abstract

This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18419454     DOI： 10.1086/587106

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  48 in total

Review 1.  Management of cytomegalovirus infection in solid organ transplantation.

Authors:  Camille N Kotton
Journal:  Nat Rev Nephrol       Date:  2010-10-26       Impact factor: 28.314

2.  Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells.

Authors:  Biswa Nath Sharma; Manfred Marschall; Christine Hanssen Rinaldo
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation.

Authors:  Sujayita Roy; Ran He; Arun Kapoor; Michael Forman; Jennifer R Mazzone; Gary H Posner; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 4.  New developments in the management of cytomegalovirus infection after solid organ transplantation.

Authors:  Albert J Eid; Raymund R Razonable
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

5.  Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.

Authors:  Robin K Avery; Ravit Arav-Boger; Kieren A Marr; Edward Kraus; Shmuel Shoham; Laura Lees; Brandon Trollinger; Pali Shah; Rich Ambinder; Dionysios Neofytos; Darin Ostrander; Michael Forman; Alexandra Valsamakis
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

6.  Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation.

Authors:  Dana G Wolf; Avichai Shimoni; Igor B Resnick; Thomas Stamminger; Avidan U Neumann; Sunwen Chou; Thomas Efferth; Orit Caplan; Jessica Rose; Arnon Nagler; Manfred Marschall
Journal:  Antiviral Res       Date:  2011-04-03       Impact factor: 5.970

7.  Human embryonic lung fibroblasts treated with artesunate exhibit reduced rates of proliferation and human cytomegalovirus infection in vitro.

Authors:  Ai-Hong Zeng; Yang-Ying Ou; Ming-Ming Guo; Xuan Dai; De-Zhi Zhou; Rui Chen
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

8.  Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers.

Authors:  Ravit Arav-Boger; Ran He; Chuang-Jiun Chiou; Jianyong Liu; Lauren Woodard; Andrew Rosenthal; Lorraine Jones-Brando; Michael Forman; Gary Posner
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

9.  Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety.

Authors:  Ran He; Michael Forman; Bryan T Mott; Rajkumar Venkatadri; Gary H Posner; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

Review 10.  Artemisinins: their growing importance in medicine.

Authors:  Sanjeev Krishna; Leyla Bustamante; Richard K Haynes; Henry M Staines
Journal:  Trends Pharmacol Sci       Date:  2008-08-25       Impact factor: 14.819
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.